Abstract
Purpose of ReviewTo describe the clinical role of CDK 4/6 inhibitors in hormone receptor-positive (HR+) metastatic breast cancer (HR+ MBC) as well as ......
小提示:本篇文献需要登录阅读全文,点击跳转登录